The Swiss health funds are expected to raise premiums in 2010 by between 9% and 20% to maintain the forecast level of reserves of 4% beyond the end of this year.
The Santesuisse organization will negotiate with the funds to call for reductions of cost growth from the current 4%-5% down to 2%-3%. Special health cost control measures are therefore likely this year.
Meanwhile, the largest fund, the Helsana group, has posted a 2008 loss of 218.0 million Swiss francs ($188.5 million) - its first deficit in eight years - after problems in capital markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze